Susceptibility of Helicobacter pylori to Levofloxacin and Rifampicin in Israel

被引:9
|
作者
Peretz, Avi [1 ]
Paritsky, Maya [2 ]
Dinisman-Zavulunov, Eleonora [3 ]
Pastukh, Nina [1 ]
Glyatman, Tatyana [1 ]
On, Avi [4 ]
机构
[1] Bar Ilan Univ, Fac Med, Clin Microbiol Lab, Baruch Padeh Med Ctr, Galilee, Israel
[2] Bar Ilan Univ, Fac Med, Gastrointestinal Unit, Baruch Padeh Med Ctr, Galilee, Israel
[3] Bar Ilan Univ, Fac Med, Serv Pharm, Baruch Padeh Med Ctr, Galilee, Israel
[4] Bar Ilan Univ, Fac Med, Pediat Gastrointestinal Unit, Baruch Padeh Med Ctr, Galilee, Israel
关键词
TRIPLE THERAPY; INFECTIONS; RESISTANCE;
D O I
10.1089/mdr.2014.0250
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to assess the resistance level of Helicobacter pylori to levofloxacin and rifampicin from samples collected from pediatric and adult Israeli patients from 2012 to 2013. A total of 117 isolate samples of H. pylori were collected between 2012 and 2013. Isolates were cultured from stomach antrum biopsies and identified by the microbiology laboratory. Isolates were considered susceptible to levofloxacin and rifampicin by an Etest. Out of 117 isolates, 105 were found susceptible and 12 resistant to levofloxacin. For rifampicin, 104 isolates were susceptible and 13 were resistant. Study results estimate an alarming resistance rate, which reiterates the need for prudent use of alternative antibiotics to prevent further spread of resistant strains. Therefore, we suggest subjecting cultures from biopsy samples to susceptibility testing for the purpose of identification of strains resistant to levofloxacin and rifampicin among other antibiotic agents. This will allow for successful monitoring of microbial resistance and will assure prudent use of antimicrobial modalities.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [41] Levofloxacin based triple therapy for third line Helicobacter pylori eradication
    Lee, M.
    Kim, G.
    Lee, B.
    Song, G.
    Park, S.
    Park, S.
    Park, J.
    Kim, S.
    HELICOBACTER, 2018, 23
  • [42] Rescue therapy with levofloxacin after multiple Helicobacter pylori treatment failures
    Gisbert, JP
    Perez-Aisa, A
    Castro-Fernandez, M
    Lamas, E
    Bermejo, F
    Ducons, J
    Fernandez-Bermejo, M
    Benito, L
    Cosme, A
    Lopez-Rivas, L
    Gisbert, JL
    Marcos, S
    Olivares, D
    Pajares, JM
    HELICOBACTER, 2005, 10 (05) : 531 - 532
  • [43] First-line triple therapy with levofloxacin for Helicobacter pylori eradication
    Gisbert, J. P.
    Fernandez Bermejo, M.
    Molina Infante, J.
    Perez Gallardo, B.
    Prieto Bermejo, A.
    Mateos Rodriguez, J.
    Robledo Andres, P.
    Gonzalez Garcia, G.
    HELICOBACTER, 2007, 12 (04) : 432 - 432
  • [44] Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis versus Nonuremic Patients
    Alirezaei, Amirhesam
    Fard, Ali Jamshidi
    Argani, Hasan
    Talaie, Ramin
    Nooraninia, Sahar
    Iranshahi, Majid
    Darvish, Parichehr
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2017, 11 (03) : 237 - 240
  • [45] MOLECULAR GENETIC DIAGNOSIS OF HELICOBACTER PYLORI AND ITS RESISTANCE TO CLARITHROMYCIN AND LEVOFLOXACIN
    Tsapkova, L. A.
    Polyakova, V. V.
    Yanova, T. I.
    Mineeva, D. T.
    Bobovskaya, T. A.
    Chegodar, A. S.
    Bordin, D. S.
    Bodunova, N. A.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (02) : 301 - 302
  • [46] Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia
    Bodunova, Natalia
    Tsapkova, Larisa
    Polyakova, Vera
    Baratova, Irina
    Rumyantsev, Konstantin
    Dekhnich, Natalia
    Nikolskaya, Karina
    Chebotareva, Margarita
    Voynovan, Irina
    Parfenchikova, Elena
    Pronina, Galina
    Chernikova, Ekaterina
    Bordin, Dmitry
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 6665 - 6674
  • [47] SUSCEPTIBILITY OF RIFAMPICIN-ISONIAZID RESISTANT MYCOBACTERIUM TUBERCULOSIS ISOLATES AGAINST LEVOFLOXACIN
    Kurniawan, Alvin Hartanto
    Mertaniasih, Ni Made
    Soedarsono
    BALI MEDICAL JOURNAL, 2016, 5 (01) : 8 - 12
  • [48] Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal
    Muhammad Miftahussurur
    Pradeep Krishna Shrestha
    Phawinee Subsomwong
    Rabi Prakash Sharma
    Yoshio Yamaoka
    BMC Microbiology, 16
  • [49] Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain
    Maria Navarro-Jarabo, Jose
    Fernandez-Sanchez, Fernando
    Fernandez-Moreno, Nuria
    Jose Hervas-Molina, Antonio
    Casado-Caballero, Francisco
    Jesus Puente-Gutierrez, Juan
    Pallares-Manrique, Hector
    Rodriguez-Ramos, Claudio
    Fernandez-Gutierrez, Clotilde
    Perez-Aisa, Angeles
    Rivas-Ruiz, Francisco
    Montiel Quezel-Guerraz, Natalia
    DIGESTION, 2015, 92 (02) : 78 - 82
  • [50] First-line triple therapy with levofloxacin for Helicobacter pylori eradication
    Gisbert, J. P.
    Fernandez-Bermejo, M.
    Molina-Infante, J.
    Perez-Gallardo, B.
    Prieto-Bermejo, A.-B.
    Mateos-Rodriguez, J.-M.
    Robledo-Andres, P.
    Gonzalez-Garcia, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) : 495 - 500